This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Jonathan Haigh
Senior Director Bioprocess Strategy & Development at FUJIFILM Diosynth Biotechnologies


Jonathan has been active in the biopharmaceutical industry for over twelve years working in both the bioprocess technology vendor and end-user sectors. Following a Ph.D. in the Institute of Biotechnology, University of Cambridge (UK), he worked for Pall Corporation (New York, US) developing and evaluating next-generation bioprocessing and analytical technologies to aid Merge and Acquisition (M&A) activities. He subsequently relocated to Fujifilm Diosynth Biotechnologies, a Contract Development and Manufacturing Organisation (CDMO) working within the Process Development function, developing DSP pre-clinical to commercial mammalian and microbial purification processes on behalf of clients through process design, scale-up to GMP manufacturer. Prior to his current role, Jonathan was Head of DSP Process Development, leading a team of 60 scientists and engineers, encompassing 10 process development laboratories and three pilot-scale facilities. Jonathan drives a number of internal and external technology and strategy development programmes towards improving protein purification capabilities and GMP operations on behalf of the business. Externally, he sits on the Biophorum Operations Group Technology Roadmap Steering Committee, is an active industrial Ph.D. viva examiner for University College London, Biochemical Engineering Department, acts on the Bioplan Associate's Biotechnology Industry Council Expert Panel, is currently pursing an MBA at the University of Durham Business School, and has a number of patents and publications pertinent to the bioprocessing field.

Agenda Sessions

  • Disruptive multi-functional downstream bioprocessing for CDMO GMP operations